MOLECULAR AND SPATIAL CHARACTERIZATION OF DRUG RESISTANCE IN HUMAN OVARIAN CANCER

Grant number: 1161198 | Funding period: 2019 - 2022

Completed

Abstract

Ovarian cancer is the most deadly gynecologic cancer in Western women. Although initially responsive to chemotherapy, drug resistance commonly evolves in a matter of months. We previously documented novel mechanisms of drug resistance in the most common form of ovarian cancer and in this study we will map their distribution within patients. We will also investigate mechanisms of resistance to a new important class of anti-cancer drugs in ovarian cancer, the PARP inhibitors.

Related publications (6)

Scholarly works icon

Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.

Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, Phineas T Hamilton, Tamara Abulez, Xuan Liu, Therese Hoang, Stuart Craig, Sian Fereday, Joy Hendley, Dale W Garsed, Katy Milne, Shreena Kalaria, Ashley Marshall, Brian L Hood, Katlin N Wilson, Kelly A Conrads, Kathleen I Pishas

2023-03-01

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, wh..

Scholarly works icon

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

Dale W Garsed, Ahwan Pandey, Sian Fereday, Catherine J Kennedy, Kazuaki Takahashi, Kathryn Alsop, Phineas T Hamilton, Joy Hendley, Yoke-Eng Chiew, Nadia Traficante, Pamela Provan, Dinuka Ariyaratne, George Au-Yeung, Nicholas W Bateman, Leanne Bowes, Alison Brand, Elizabeth L Christie, Julie M Cunningham, Michael Friedlander, Bronwyn Grout

2022-12-01

Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after d..

Scholarly works icon

High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival

Katharine K Brieger, Minh Tung Phung, Bhramar Mukherjee, Kelly M Bakulski, Hoda Anton-Culver, Elisa Bandera, David DL Bowtell, Daniel W Cramer, Anna DeFazio, Jennifer A Doherty, Sian Fereday, Renee Turzanski Fortner, Aleksandra Gentry-Maharaj, Ellen L Goode, Marc T Goodman, Holly R Harris, Keitaro Matsuo, Usha Menon, Francesmary Modugno, Kirsten B Moysich

2022-02-01

BACKGROUND: There is suggestive evidence that inflammation is related to ovarian cancer survival. However, more research is needed..

Scholarly works icon

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer

Kathleen Pishas, Karla J Cowley, Ahwan Pandey, Therese Hoang, Jessica A Beach, Jennii Luu, Robert Vary, Lorey K Smith, Carolyn E Shembrey, Nineveh Rashoo, Madelynne O White, Kaylene J Simpson, Andrea Bild, Jason Griffiths, Dane Cheasley, Ian Campbell, David DL Bowtell, Elizabeth L Christie

2021-11-01

Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC)..

Scholarly works icon

Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.

Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild

2021-07-01

The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...

Scholarly works icon

The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer

EL Christie, AE Freimund, S Fereday, K Alsop, T Hoang, K Pishas, G Au-Yeung, M Friedlander, DD Bowtell

2020-01-01

BRCA1 and BRCA2 tumor suppressor genes are central components of the homologous recombination (HR) DNA repair pathway, a high-fide..